Mismatch negativity (MMN) deficiency: A break-through biomarker in predicting psychosis onset

International Journal of Psychophysiology

Volumn 95, Issue 3, 2015, Pages 338-344

  Näätänen, Risto ^a,b,c   Shiga, Tetsuya ^d   Asano, Satoko ^d   Yabe, Hirooki ^d  

^a UNIVERSITY OF TARTU   (Estonia)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF HELSINKI   (Finland)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

At risk mental state (ARMS); Event related potential (ERP); Mismatch negativity (MMN); Prediction; Psychosis; Schizophrenia; Ultra high risk

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; DISEASE MARKER; EVENT RELATED POTENTIAL; FUNCTIONAL DISEASE; GLOBAL ASSESSMENT OF FUNCTIONING; HIGH RISK PATIENT; HUMAN; MAGNETOENCEPHALOGRAPHY; MENTAL HEALTH; MISMATCH NEGATIVITY; NERVE CELL PLASTICITY; PREDICTION; PREDICTIVE VALUE; PSYCHOSIS; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; BRAIN; CONTINGENT NEGATIVE VARIATION; ELECTROENCEPHALOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS;

BRAIN; CONTINGENT NEGATIVE VARIATION; ELECTROENCEPHALOGRAPHY; HUMANS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS;

EID: 84923386113     PISSN: 01678760     EISSN: 18727697     Source Type: Journal    
DOI: 10.1016/j.ijpsycho.2014.12.012     Document Type: Article

References (139)

1. Alain C., Hargrave R., Woods D.L. Processing of auditory stimuli during visual attention in patients with schizophrenia. Biol. Psychiatry 1998, 44:1151-1159.
2. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
3. Astikainen P., Stefanics G., Nokia M., Lipponen A., Cong F., Penttonen M., Ruusuvirta T. Memory-based mismatch response to frequency changes in rats. PLoS One 2011, 6:e24208. (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0039434).
4. Atkinson R.J., Michie P.T., Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol. Psychiatry 2012, 71:98-104.
5. Baker K., Baldeweg T., Sivagnanasundaram S., Scambler P., Skuse D. COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol. Psychiatry 2005, 58:23-31.
6. Baldeweg T., Hirsch S.R. Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: a comparison with bipolar disorder and Alzheimer's disease. Int. J. Psychophysiol. 2014, http://www.sciencedirect.com/science/article/pii/S0167876014000774, (Mar 26. [Epub ahead of print]).
7. Baldeweg T., Wong D., Stephan K.E. Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials. Int. J. Psychophysiol. 2006, 59:49-58.
8. Banati R., Hickie I.B. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med. J. Aust. 2009, 190:S26-S32.
9. Bar-Haim Y., Marshall P.J., Fox N.A., Schorr E.A., Gordon-Salant S. Mismatch negativity in socially withdrawn children. Biol. Psychiatry 2003, 54:17-24.
10. Belger A., Yucel G.H., Donkers F.C. In search of psychosis biomarkers in high-risk populations: is the mismatch negativity the one we've been waiting for?. Biol. Psychiatry 2012, 71:94-95.
11. Bodatsch M., Ruhrmann S., Wagner M., Müller R., Schultze-Lutter F., Frommann I., Brinkmeyer J., Gaebel W., Maier W., Klosterkötter J., Brockhaus-Dumke A. Prediction of psychosis by mismatch negativity. Biol. Psychiatry 2011, 69:959-966.
12. Bodatsch M., Klosterkötter J., Daumann J. Contributions of experimental psychiatry to research on the psychosis prodrome. Fron. Psychiatry 2013, 4:170. (http://journal.frontiersin.org/Journal/10.3389/fpsyt.2013.00170/full).
13. Bodatsch M., Klosterkötter J., Müller R., Ruhrmann S. Basic disturbances of information processing in psychosis prediction. Front. Psychiatry 2013, 4:93. (http://journal.frontiersin.org/Journal/10.3389/fpsyt.2013.00093/full).
14. Brewer W.J., Francey S.M., Wood S.J., Jackson H.J., Pantelis C., Phillips L.J., Yung A.R., Anderson V.A., McGorry P.D. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry 2005, 162:71-78.
15. Brockhaus-Dumke A., Tendolkar I., Pukrop R., Schultze-Lutter F., Klosterkötter J., Ruhrmann S. Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr. Res. 2005, 73:297-310.
16. Butler P.D., Chen Y., Ford J.M., Geyer M.A., Silverstein S.M., Green M.F. Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr. Bull. 2012, 38:81-91.
17. Caspi A., Reichenberg A., Weiser M., Rabinowitz J., Kaplan Z., Knobler H., Davidson-Sagi N., Davidson M. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr. Res. 2003, 65:87-94.
18. Catts S.V., Shelley A.M., Ward P.B., Liebert B., McConaghy N., Andrews S., Michie P.T. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am. J. Psychiatry 1995, 152:213-219.
19. Cowan N., Winkler I., Teder W., Näätänen R. Memory prerequisites of mismatch negativity in the auditory event-related potential (ERP). J. Exp. Psychol. Learn. Mem. Cogn. 1993, 19:909-921.
20. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:365-384.
21. Coyle J.T., Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berlin) 2004, 174:32-38.
22. Csépe V., Karmos G., Molnár M. Evoked potential correlates of stimulus deviance during wakefulness and sleep in cat - animal model of mismatch negativity. Electroencephalogr. Clin. Neurophysiol. 1987, 66:571-578.
23. Devrim-Uçok M., Keskin-Ergen H.Y., Uçok A. Mismatch negativity at acute and post-acute phases of first-episode schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258:179-185.
24. Dulude L., Labelle A., Knott V.J. Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. J. Clin. Psychopharmacol. 2010, 30:541-548.
25. Dunbar G., Boeijinga P.H., Demazières A., Cisterni C., Kuchibhatla R., Wesnes K., Luthringer R. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 2007, 191:919-929.
26. Egerton A., Stone J.M. The glutamate hypothesis of schizophrenia: neuroimaging and drug development. Curr. Pharm. Biotechnol. 2012, 13:1500-1512.
27. Egerton A., Chaddock C.A., Winton-Brown T.T., Bloomfield M.A., Bhattacharyya S., Allen P., McGuire P.K., Howes O.D. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 2013, 74:106-112.
28. Ehrlichman R.S., Luminais S.N., White S.L., Rudnick N.D., Ma N., Dow H.C., Kreibich A.S., Abel T., Brodkin E.S., Hahn C.G., Siegel S.J. Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Res. 2009, 1294:116-127.
29. Fisher D.J., Grant B., Smith D.M., Borracci G., Labelle A., Knott V.J. Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified 'optimal' multi-feature paradigm. Int. J. Psychophysiol. 2011, 81:245-251.
30. Fisher D.J., Grant B., Smith D.M., Borracci G., Labelle A., Knott V.J. Nicotine and the hallucinating brain: effects on mismatch negativity (MMN) in schizophrenia. Psychiatry Res. 2012, 196:181-187.
31. Fisher D.J., Labelle A., Knott V.J. Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Schizophr. Res. 2012, 139:237-245.
32. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rössler A., Schultze-Lutter F., Keshavan M., Wood S., Ruhrmann S., Seidman L.J., Valmaggia L., Cannon T., Velthorst E., De Haan L., Cornblatt B., Bonoldi I., Birchwood M., McGlashan T., Carpenter W., McGorry P., Klosterkötter J., McGuire P., Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
33. Giard M.H., Perrin F., Pernier J., Bouchet P. Brain generators implicated in the processing of auditory stimulus deviance: a topographic event-related potential study. Psychophysiology 1990, 27:627-640.
34. Gil-da-Costa R., Stoner G.R., Fung R., Albright T.D. Nonhuman primate model of schizophrenia using a noninvasive EEG method. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:15425-15430.
35. Hari R., Hämäläinen M., Ilmoniemi R., Kaukoranta E., Reinikainen K., Salminen J., Alho K., Näätänen R., Sams M. Responses of the primary auditory cortex to pitch changes in a sequence of tone pips: neuromagnetic recordings in man. Neurosci. Lett. 1984, 50:127-132.
36. Hayakawa Y.K., Kirino E., Shimoji K., Kamagata K., Hori M., Ito K., Kunimatsu A., Abe O., Ohtomo K., Aoki S. Anterior cingulate abnormality as a neural correlate of mismatch negativity in schizophrenia. Neuropsychobiology 2013, 68:197-204.
37. Heekeren K., Daumann J., Neukirch A., Stock C., Kawohl W., Norra C., Waberski T.D., Gouzoulis-Mayfrank E. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berlin) 2008, 199:77-88.
38. Hermens D.F., Ward P.B., Hodge M.A., Kaur M., Naismith S.L., Hickie I.B. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:822-829.
39. Higuchi Y., Sumiyoshi T., Kawasaki Y., Ito T., Seo T., Suzuki M. Effect of tandospirone on mismatch negativity and cognitive performance in schizophrenia: a case report. J. Clin. Psychopharmacol. 2010, 30:732-734.
40. Higuchi Y., Sumiyoshi T., Seo T., Miyanishi T., Kawasaki Y., Suzuki M. Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. PLoS One 2013, 8:e54080. (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0054080).
41. Higuchi Y., Seo T., Miyanishi T., Kawasaki Y., Suzuki M., Sumiyoshi T. Mismatch negativity and p3a/reorienting complex in subjects with schizophrenia or at-risk mental state. Front. Behav. Neurosci. 2014, 8:172. (http://journal.frontiersin.org/Journal/10.3389/fnbeh.2014.00172/full).
42. Horton J., Millar A., Labelle A., Knott V.J. MMN responsivity to manipulations of frequency and duration deviants in chronic, clozapine-treated schizophrenia patients. Schizophr. Res. 2011, 126:202-211.
43. Hsieh M.H., Shan J.C., Huang W.L., Cheng W.C., Chiu M.J., Jaw F.S., Hwu H.G., Liu C.C. Auditory event-related potential of subjects with suspected pre-psychotic state and first-episode psychosis. Schizophr. Res. 2012, 140:243-249.
44. Inami R., Kirino E., Inoue R., Arai H. Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol. Biochem. Behav. 2005, 80:453-461.
45. Jahshan C., Cadenhead K.S., Rissling A.J., Kirihara K., Braff D.L., Light G.A. Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol. Med. 2012, 42:85-97.
46. Javitt D.C., Doneshka P., Zylberman I., Ritter W., Vaughan H.G. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol. Psychiatry 1993, 33:513-519.
47. Javitt D.C., Steinschneider M., Schroeder C.E., Vaughan H.G., Arezzo J.C. Detection of stimulus deviance within primate primary auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res. 1994, 667:192-200.
48. Javitt D.C., Steinschneider M., Schroeder C.E., Arezzo J.C. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11962-11967.
49. Javitt D.C., Strous R.D., Grochowski S., Ritter W., Cowan N. Impaired precision, but normal retention, of auditory sensory ("echoic") memory information in schizophrenia. J. Abnorm. Psychol. 1997, 106:315-324.
50. Javitt D.C., Shelley A.M., Silipo G., Lieberman J.A. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch. Gen. Psychiatry 2000, 57:1131-1137.
51. Javitt D.C., Zukin S.R., Heresco-Levy U., Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr. Bull. 2012, 38:958-966.
52. Kähkönen S., Mäkinen V., Jääskeläinen I.P., Pennanen S., Liesivuori J., Ahveninen J. Serotonergic modulation of mismatch negativity. Psychiatry Res. 2005, 138:61-74.
53. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 2010, 83:108-121.
54. Kantrowitz J.T., Javitt D.C. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses 2010, 4:189-200.
55. Kasai K., Okazawa K., Nakagome K., Hiramatsu K., Hata A., Fukuda M., Honda M., Miyauchi M., Matsushita M. Mismatch negativity and N2b attenuation as an indicator for dysfunction of the preattentive and controlled processing for deviance detection in schizophrenia: a topographic event-related potential study. Schizophr. Res. 1999, 35:141-156.
56. Kasai K., Yamada H., Kamio S., Nakagome K., Iwanami A., Fukuda M., Yumoto M., Itoh K., Koshida I., Abe O., Kato N. Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An EEG and MEG study. Clin. Neurophysiol. 2002, 113:141-150.
57. Kaur M., Battisti R.A., Ward P.B., Ahmed A., Hickie I.B., Hermens D.F. MMN/P3a deficits in first episode psychosis: comparing schizophrenia-spectrum and affective-spectrum subgroups. Schizophr. Res. 2011, 130:203-209.
58. Kaur M., Lagopoulos J., Ward P.B., Watson T.L., Naismith S.L., Hickie I.B., Hermens D.F. Mismatch negativity/P3a complex in young people with psychiatric disorders: a cluster analysis. PLoS One 2012, 7:e51871. (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0051871).
59. Kaur M., Lagopoulos J., Lee R.S., Ward P.B., Naismith S.L., Hickie I.B., Hermens D.F. Longitudinal associations between mismatch negativity and disability in early schizophrenia- and affective-spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:161-169.
60. Kawakubo Y., Kasai K. Support for an association between mismatch negativity and social functioning in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1367-1368.
61. Kawakubo Y., Kasai K., Kudo N., Rogers M.A., Nakagome K., Itoh K., Kato N. Phonetic mismatch negativity predicts verbal memory deficits in schizophrenia. Neuroreport 2006, 17:1043-1046.
62. Kawakubo Y., Kamio S., Nose T., Iwanami A., Nakagome K., Fukuda M., Kato N., Rogers M.A., Kasai K. Phonetic mismatch negativity predicts social skills acquisition in schizophrenia. Psychiatry Res. 2007, 152:261-265.
63. Kayser J., Tenke C.E., Kroppmann C.J., Alschuler D.M., Fekri S., Ben-David S., Corcoran C.M., Bruder G.E. Auditory event-related potentials and alpha oscillations in the psychosis prodrome: neuronal generator patterns during a novelty oddball task. Int. J. Psychophysiol. 2014, 91:104-120.
64. Keshavan M.S., DeLisi L.E., Seidman L.J. Early and broadly defined psychosis risk mental states. Schizophr. Res. 2011, 126:1-10.
65. Kiang M., Light G.A., Prugh J., Coulson S., Braff D.L., Kutas M. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J. Int. Neuropsychol. Soc. 2007, 13:653-663.
66. Kiang M., Braff D.L., Sprock J., Light G.A. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin. Neurophysiol. 2009, 120:1949-1957.
67. Knott V., Impey D., Philippe T., Smith D., Choueiry J., de la Salle S., Dort H. Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study. Hum. Psychopharmacol. 2014, 29:446-458.
68. Kraus N., McGee T., Carrell T., King C., Littman T., Nicol T. Discrimination of speech-like contrasts in the auditory thalamus and cortex. J. Acoust. Soc. Am. 1994, 96:2758-2768.
69. Kreitschmann-Andermahr I., Rosburg T., Meier T., Volz H.P., Nowak H., Sauer H. Impaired sensory processing in male patients with schizophrenia: a magnetoencephalographic study of auditory mismatch detection. Schizophr. Res. 1999, 35:121-129.
70. Laurens K.R., Hodgins S., Maughan B., Murray R.M., Rutter M.L., Taylor E.A. Community screening for psychotic-like experiences and other putative antecedents of schizophrenia in children aged 9-12 years. Schizophr. Res. 2007, 90:130-146.
71. Laurens K.R., Hodgins S., Mould G.L., West S.A., Schoenberg P.L., Murray R.M., Taylor E.A. Error-related processing dysfunction in children aged 9 to 12years presenting putative antecedents of schizophrenia. Biol. Psychiatry 2010, 67:238-245.
72. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D., Fornari E., Meuli R., Solida A., Vianin P., Cuénod M., Buclin T., Do K.Q. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
73. Lawrie S.M., Olabi B., Hall J., McIntosh A.M. Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?. World Psychiatry : Off. J. World Psychiatr. Assoc. 2011, 10:19-31.
74. Lee S.H., Sung K., Lee K.S., Moon E., Kim C.G. Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48:213-219.
75. Leung S., Croft R.J., Baldeweg T., Nathan P.J. Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects. Psychopharmacology (Berl.) 2007, 194:443-451.
76. Light G.A., Braff D.L. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry 2005, 62:127-136.
77. Light G.A., Braff D.L. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am. J. Psychiatry 2005, 162:1741-1743.
78. Light G.A., Näätänen R. Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:15175-15176.
79. Light G.A., Swerdlow N.R., Braff D.L. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J. Cogn. Neurosci. 2007, 19:1624-1632.
80. Light G.A., Swerdlow N.R., Rissling A.J., Radant A., Sugar C.A., Sprock J., Pela M., Geyer M.A., Braff D.L. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One 2012, 7:e39434. (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0039434).
81. Lin Y.T., Liu C.M., Chiu M.J., Liu C.C., Chien Y.L., Hwang T.J., Jaw F.S., Shan J.C., Hsieh M.H., Hwu H.G. Differentiation of schizophrenia patients from healthy subjects by mismatch negativity and neuropsychological tests. PLoS One 2012, 7:e34454. (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0034454).
82. Luck S.J., Mathalon D.H., O'Donnell B.F., Hämäläinen M.S., Spencer K.M., Javitt D.C., Uhlhaas P.J. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol. Psychiatry 2011, 70:28-34.
83. Magno E., Yeap S., Thakore J.H., Garavan H., De Sanctis P., Foxe J.J. Are auditory-evoked frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic schizophrenia. Biol. Psychiatry 2008, 64:385-391.
84. Martin L.F., Davalos D.B., Kisley M.A. Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nicotine Tob. Res. 2009, 11:698-706.
85. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 2000, 57:637-648.
86. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59:921-928.
87. Michie P.T. What has MMN revealed about the auditory system in schizophrenia?. Int. J. Psychophysiol. 2001, 42:177-194.
88. Miyanishi T., Sumiyoshi T., Higuchi Y., Seo T., Suzuki M. LORETA current source density for duration mismatch negativity and neuropsychological assessment in early schizophrenia. PLoS One 2013, 8:e61152. (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0061152).
89. Molholm S., Martinez A., Ritter W., Javitt D.C., Foxe J.J. The neural circuitry of pre-attentive auditory change-detection: an fMRI study of pitch and duration mismatch negativity generators. Cereb. Cortex 2005, 15:545-551.
90. Murphy J.R., Rawdon C., Kelleher I., Twomey D., Markey P.S., Cannon M., Roche R.A. Reduced duration mismatch negativity in adolescents with psychotic symptoms: further evidence for mismatch negativity as a possible biomarker for vulnerability to psychosis. BMC Psychiatry 2013, 13:45. (http://www.biomedcentral.com/1471-244X/13/45).
91. Näätänen R., Kähkönen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int. J. Neuropsychopharmacol. 2009, 12:125-135.
92. Näätänen R., Gaillard A.W., Mäntysalo S. Early selective-attention effect on evoked potential reinterpreted. Acta Psychol. 1978, 42:313-329.
93. Näätänen R., Pakarinen S., Rinne T., Takegata R. The mismatch negativity (MMN): towards the optimal paradigm. Clin. Neurophysiol. 2004, 115:140-144.
94. Näätänen R., Kujala T., Kreegipuu K., Carlson S., Escera C., Baldeweg T., Ponton C. The mismatch negativity: an index of cognitive decline in neuropsychiatric and neurological diseases and in ageing. Brain 2011, 134:3435-3453.
95. Näätänen R., Kujala T., Escera C., Baldeweg T., Kreegipuu K., Carlson S., Ponton C. The mismatch negativity (MMN)-a unique window to disturbed central auditory processing in ageing and different clinical conditions. Clin. Neurophysiol. 2012, 123:424-458.
96. Näätänen R., Sussman E.S., Salisbury D., Shafer V.L. Mismatch negativity (MMN) as an index of cognitive dysfunction. Brain Topogr. 2014, 27:451-466.
97. Nagai T., Tada M., Kirihara K., Araki T., Jinde S., Kasai K. Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review. Front. Psychiatry 2013, 4:115. (http://journal.frontiersin.org/Journal/10.3389/fpsyt.2013.00115/full).
98. Nakamura T., Michie P.T., Fulham W.R., Todd J., Budd T.W., Schall U., Hunter M., Hodgson D.M. Epidural auditory event-related potentials in the rat to frequency and duration deviants: evidence of mismatch negativity?. Front. Psychol. 2011, 2:367. (http://journal.frontiersin.org/Journal/10.3389/fpsyg.2011.00367/full).
99. Nimchinsky E.A., Sabatini B.L., Svoboda K. Structure and function of dendritic spines. Annu. Rev. Physiol. 2002, 64:313-353.
100. Niznikiewicz M.A., Spencer K.M., Dickey C., Voglmaier M., Seidman L.J., Shenton M.E., McCarley R.W. Abnormal pitch mismatch negativity in individuals with schizotypal personality disorder. Schizophr. Res. 2009, 110:188-193.
101. Pakarinen S., Takegata R., Rinne T., Huotilainen M., Näätänen R. Measurement of extensive auditory discrimination profiles using the mismatch negativity (MMN) of the auditory event-related potential (ERP). Clin. Neurophysiol. 2007, 118:177-185.
102. Pekkonen E., Hirvonen J., Ahveninen J., Kähkönen S., Kaakkola S., Huttunen J., Jääskeläinen I.P. Memory-based comparison process not attenuated by haloperidol: a combined MEG and EEG study. Neuroreport 2002, 13:177-181.
103. Perez V.B., Swerdlow N.R., Braff D.L., Näätänen R., Light G.A. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark. Med 2014, 8:9-14.
104. Perez V.B., Woods S.W., Roach B.J., Ford J.M., McGlashan T.H., Srihari V.H., Mathalon D.H. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol. Psychiatry 2014, 75:459-469.
105. Rasser P.E., Schall U., Todd J., Michie P.T., Ward P.B., Johnston P., Helmbold K., Case V., Søyland A., Tooney P.A., Thompson P.M. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr. Bull. 2011, 37:131-140.
106. Rissling A.J., Light G.A. Neurophysiological measures of sensory registration, stimulus discrimination, and selection in schizophrenia patients. Curr. Top. Behav. Neurosci. 2010, 4:283-309.
107. Rissling A.J., Makeig S., Braff D.L., Light G.A. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr. Psychiatr. Rep. 2010, 12:572-578.
108. Rössler W., Hengartner M.P., Ajdacic-Gross V., Haker H., Gamma A., Angst J. Sub-clinical psychosis symptoms in young adults are risk factors for subsequent common mental disorders. Schizophr. Res. 2011, 131:18-23.
109. Ruhrmann S., Schultze-Lutter F., Salokangas R.K., Heinimaa M., Linszen D., Dingemans P., Birchwood M., Patterson P., Juckel G., Heinz A., Morrison A., Lewis S., von Reventlow H.G., Klosterkötter J. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry 2010, 67:241-251.
110. Rund B.R. Is there a degenerative process going on in the brain of people with schizophrenia?. Front. Hum. Neurosci. 2009, 3:36. (http://journal.frontiersin.org/Journal/10.3389/neuro.09.036.2009/full).
111. Salisbury D.F., Shenton M.E., Griggs C.B., Bonner-Jackson A., McCarley R.W. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch. Gen. Psychiatry 2002, 59:686-694.
112. Salisbury D.F., Kuroki N., Kasai K., Shenton M.E., McCarley R.W. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch. Gen. Psychiatry 2007, 64:521-529.
113. Schmidt A., Bachmann R., Kometer M., Csomor P.A., Stephan K.E., Seifritz E., Vollenweider F.X. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology 2012, 37:865-875.
114. Schreiber H., Stolz-Born G., Kornhuber H.H., Born J. Event-related potential correlates of impaired selective attention in children at high risk for schizophrenia. Biol. Psychiatry 1992, 32:634-651.
115. Schwartz T.L., Sachdeva S., Stahl S.M. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front. Pharmacol. 2012, 3:195. (http://journal.frontiersin.org/Journal/10.3389/fphar.2012.00195/full).
116. Shaikh M., Valmaggia L., Broome M.R., Dutt A., Lappin J., Day F., Woolley J., Tabraham P., Walshe M., Johns L., Fusar-Poli P., Howes O., Murray R.M., McGuire P., Bramon E. Reduced mismatch negativity predates the onset of psychosis. Schizophr. Res. 2012, 134:42-48.
117. Shalgi S., Deouell L.Y. Direct evidence for differential roles of temporal and frontal components of auditory change detection. Neuropsychologia 2007, 45:1878-1888.
118. Shelley A.M., Ward P.B., Catts S.V., Michie P.T., Andrews S., McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol. Psychiatry 1991, 30:1059-1062.
119. Shin K.S., Kim J.S., Kang D.H., Koh Y., Choi J.S., O'Donnell B.F., Chung C.K., Kwon J.S. Pre-attentive auditory processing in ultra-high-risk for schizophrenia with magnetoencephalography. Biol. Psychiatry 2009, 65:1071-1078.
120. Simon A.E., Velthorst E., Nieman D.H., Linszen D., Umbricht D., de Haan L. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr. Res. 2011, 132:8-17.
121. Stafford M.R., Jackson H., Mayo-Wilson E., Morrison A.P., Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013, 346:f185. (http://www.bmj.com/content/346/bmj.f185.long).
122. Stone J.M., Day F., Tsagaraki H., Valli I., McLean M.A., Lythgoe D.J., O'Gorman R.L., Barker G.J., McGuire P.K. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66:533-539.
123. Stone J.M., Bramon E., Pauls A., Sumich A., McGuire P.K. Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials. Psychiatry Res. 2010, 183:174-176.
124. Sumiyoshi T., Miyanishi T., Seo T., Higuchi Y. Electrophysiological and neuropsychological predictors of conversion to schizophrenia in at-risk subjects. Front. Behav. Neurosci. 2013, 7:148. (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801084/).
125. Takahashi H., Rissling A.J., Pascual-Marqui R., Kirihara K., Pela M., Sprock J., Braff D.L., Light G.A. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage 2012, 66C:594-603.
126. Thönnessen H., Zvyagintsev M., Harke K.C., Boers F., Dammers J., Norra C., Mathiak K. Optimized mismatch negativity paradigm reflects deficits in schizophrenia patients. A combined EEG and MEG study. Biol. Psychol. 2008, 77:205-216.
127. Todd J., Michie P.T., Schall U., Karayanidis F., Yabe H., Näätänen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol. Psychiatry 2008, 63:58-64.
128. Todd J., Harms L., Schall U., Michie P.T. Mismatch negativity: translating the potential. Front. Psychiatry 2013, 4:171. (http://journal.frontiersin.org/Journal/10.3389/fpsyt.2013.00171/full).
129. Todd J., Whitson L., Smith E., Michie P.T., Schall U., Ward P.B. What's intact and what's not within the mismatch negativity system in schizophrenia. Psychophysiology 2014, 51:337-347.
130. Toyomaki A., Kusumi I., Matsuyama T., Kako Y., Ito K., Koyama T. Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:95-99.
131. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 2007, 33:69-94.
132. Turetsky B.I., Bilker W.B., Siegel S.J., Kohler C.G., Gur R.E. Profile of auditory information-processing deficits in schizophrenia. Psychiatry Res. 2009, 165:27-37.
133. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 76:1-23.
134. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 2000, 57:1139-1147.
135. Umbricht D., Koller R., Vollenweider F.X., Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 2002, 51:400-406.
136. Wienberg M., Glenthoj B.Y., Jensen K.S., Oranje B. A single high dose of escitalopram increases mismatch negativity without affecting processing negativity or P300 amplitude in healthy volunteers. J. Psychopharmacol. 2010, 24:1183-1192.
137. Wynn J.K., Sugar C., Horan W.P., Kern R., Green M.F. Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol. Psychiatry 2010, 67:940-947.
138. Yamasue H., Yamada H., Yumoto M., Kamio S., Kudo N., Uetsuki M., Abe O., Fukuda R., Aoki S., Ohtomo K., Iwanami A., Kato N., Kasai K. Abnormal association between reduced magnetic mismatch field to speech sounds and smaller left planum temporale volume in schizophrenia. NeuroImage 2004, 22:720-727.
139. Zhou Z., Zhu H., Chen L. Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia. PLoS One 2013, e52186. (http://dx.plos.org/10.1371/journal.pone.0052186).